Today, health-care analysts David Williamson and Brenton Flynn look at Sarepta's nearly 200% share-price jump recently. 

The company had some very favorable results with its revolutionary cystic fibrosis drug, and though it's only positioned to capture a small slice of the market currently, the potential to develop similar drugs that would target a larger patient population is enormous. The company could go even higher from here without such developments as well, as both Brenton and David see it as a reasonable buyout candidate. Even after the pop, it may still have room to run.

When it comes to do-or-die businessea, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.